News
-
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE
Pentixapharm signs manufacturing agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE to produce CXCR4-targeting radiotherapeutic doses for clinical trials -
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year
Pentixapharm Holding AG releases 2024 financial results with EUR 12.8 million net loss and guides for EUR 23.5 million loss in 2025, focusing on R&D and operating expenses -
-
-
-